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LETTERS TO THE EDITOR 
Modulation of alloreactivity in transplant 
recipients by phenotypic manipulation of donor 
endothelium 
To the Editor: 
I read with interest he report by Quigley and associates 
(J THORAC CARDIOVASC SURG 1995;109:905-9) of their 
observations concerning rat cardiac allograft prolongation 
by pretreatment of the donor with intravascular injection 
of recipient ype endothelial cells. Clearly such a simple 
approach could have direct clinical application. What is 
less clear is the interpretation of this interesting phenom- 
enon. The title of the report suggests two things: (1) that 
the alloreactivity of the recipient has been altered and (2) 
that phenotypic manipulation of the donor endothelium 
itself has occurred. Unfortunately, there seems to be little 
evidence of the latter, and because of the lack of appro- 
priate controls the article offers inadequate information 
with respect o the former. 
Evidence is presented that recipient-type ndothelial 
cells have "seeded the graft." An argument ispresented in 
the discussion segment that these endothelial cells "pro- 
liferate in the allograft vascular tree"; however, there is no 
direct evidence of such proliferation provided. Further- 
more, although the authors uggest that immunomodula- 
tion is occurring by "either masking the expression of the 
class II MHC [major histocompatibility complex] mole- 
cules or causing up-regulation or down-regulation of 
MHC or cell adhesion genes (or both) in the donor 
endothelium," they offer no immunohistochemical evi- 
dence of any of these potential mechanisms. The breadth 
of this hypothetical mechanism is such that it is of limited 
usefulness in the interpretation of the data. Furthermore, 
no direct evidence is provided that the donor endothelium 
is an any way phenotypically modified. Again, an immu- 
nohistochemical study demonstrating staining of endothe- 
lial cells with markers identifying the cells as donor in 
origin counterstained to demonstrate the hypothesized 
phenotypic modification would be more helpful. This is 
not to say that phenotypic modification did not occur. We 
simply do not know. 
The studies presented leave us equally uninformed 
regarding the effect of this donor graft pretreatment on 
alloreactivity. Skin graft data are presented emonstrating 
(remarkably) neither prolongation or accelerated rejec- 
tion of donor-specific skin grafts in animals bearing 
treated grafts. That is, there is no effect on these grafts as 
compared with those of animals treated with subtherapeu- 
tic cyclosporine. Unfortunately, inasmuch as the hypoth- 
esis of this study is stated to be the effect of manipulation 
of allograft endothelium by means of recipient-type endo- 
thelial seeding, an additional crucial control would be an 
animal given an unmodified heart graft. Rejection of the 
skin graft does not cause rejection of the heart graft. It is 
as if the recipient is immunologically blind to the modified 
graft, a very intriguing observation! Unfortunately, this 
does not quite square with the mixed lymphocyte culture 
data presented, which actually demonstrate some evi- 
dence of sensitization to donor-type cells. Although the 
stimulation index is globally reduced (most likely as a 
result of cyclosporine immunosuppression, as acknowl- 
edged by the authors), the peak in the point of maximal 
proliferation is advanced from day 8 to day 6 as compared 
with proliferation in untreated animals. Again, a crucial 
control would be comparison with an animal receiving an 
unmodified graft. This control would address the question 
of whether the alloreactivity of the recipients has been 
modified by pretreatment of the donor graft. 
The studies described by Quigley and associates are an 
exciting inverse of the classic enhancement experiments 
also performed with vascularized grafts in rats. In these, 
injection of donor-type cells into the host produced graft 
prolongation that appeared to be due to a local phenom- 
enon that was transferrable with the graft itself on retrans- 
plantation. Retransplantation f these heart grafts into 
naive recipients might help to answer the question of 
whether some sort of local suppression is active. If so, 
would the authors consider this a form of local tolerance? 
Thoralf M. Sundt IH, MD 
Assistant Professor of Surgery 
Washington University School of Medicine 
St. Louis, 340 63110 
12/8/68742 
Reply to the Editor: 
My colleagues and I appreciate the comments by 
Dr. Sundt regarding our article "Modulation of Atloreac- 
tivity in Transplant Recipients by Phenotypic Manipula- 
tion of Donor Endothelium." We must emphasize that 
these data represent a "pilot" project only and that the 
mechanism of the observed phenomenon is yet to be 
established. As outlined, our conclusions are hypotheses 
presently under investigation. 
When the study was initially designed, we realized that 
the most definitive trafficking study would include trans- 
fection of the host endothelial cells with a vector that is 
replication defective and that contains /3-galactosidase 
and neomycin-resistant genes. Incubation of transplant 
sections with X-gal chromagen would demonstrate blue 
chromatin if transfected cells were present. At the time, 
our laboratory did not have such technology (Nabel et al. 
Science 1990;244:1342-4). tn this pilot project, we substi- 
tuted the fluorescent cell label for this sophisticated 
technique. Although this latter method is somewhat prim- 
itive, we were satisfied that with simple fluorescent light 
microscopy, these labeled cells remained in the vessel 
wall, because we could easily differentiate blood vessels 
from the myocardial parenchyma. One would have ex- 
pected this "tag" to be located in the extravascular space 
(in association with macrophages) if the labeled cells were 
not viable. We could not demonstrate any PKH 26 dye 
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(Zynaxis Cell Sciences, Inc., Malvern, Pa.) outside the 
vascular tree, even 15 days after graft perfusion. 
We agree that a double-staining immunofluorescence 
technique to demonstrate phenotypic modification would 
support our hypothesis; however, our initial attempts at 
this were technically unsuccessful. In fact, we used OX 3 
(Lewis) and MCA 13 (Brown Norway), monoclonal anti- 
bodies (Harlan Bioproducts~ Indianapolis, Ind.) labeled 
with fluoroscein and rhodopsin, respectively, but we were 
unable to reproducibly stain even our control sections. 
We used mixed lymphocyte culture and skin grafting as 
our method to determine tolerance. Both of these are old, 
unchallenged, standard models in transplantation biology. 
One must interpret he results of such experiments with 
caution, particularly in the context of both sensitization 
and chemical immunosuppression, as was the case in this 
study. We agree that retransplantation of thes e hearts into 
naive recipients would offer some insight into the mech- 
anism of this phenomenon (ie., pan suppression vs. local 
Suppression). 
In conc!usion, we remain excited about the results of 
this very simple mode ! involving manipulation of an 
allograft o promote long-term survival. We hope that this 
initial report will stimulae other laboratories to refocus 
their research at the donor organ rather than the recipi- 
ent. 
Robert L. Quigley, MD, PhD 
Section of Cardiothoracic Surgery 
Guthrie Clinic Ltd. 
Guthrie Square 
Sayre, PA 18840 
12/8/68741 
On dynamic ardiomyoplasty 
To the Editor: 
At the completion of its first decade in clinical use, 
dynamic cardiomyoplasty is being judged on the basis of 
its late results. A realistic scrutiny shows limited or no 
value of the current technique of cardiomyoplasty, espe- 
cially in terms of unctional assistance to cardiac muscle 
rather than as a structural support. 1 However, this con- 
clusion is a result of the disadvantaged debut of the tech- 
nique, with inadequate background experimentation, and 
should not suggest its abandonment. 
The distal portion of the latissimus dorsi muscle, which 
is wrapped around the heart and the function of which is 
vital to the overall success of the procedure, has been 
experimentally and clinically shown to undergo fatty de- 
generation, atrophy, and fibrosis after dynamic cardiom- 
yoplasty. 2'3 This portion of the latissimus dorsi muscle 
derives its blood supply mostly from the perforating 
vessels, two of which are always of considerable size 4 and 
are cut during surgical elevation of the muscle. Although 
the importance of these perforating vessels in muscle 
perfusion is different from species to species, it seems that 
in human beings, especially under demanding condition s 
such as in dynamic cardiomyoplasty, perfusion through 
these vessels is crucial. One technique that can be applied 
to overcome this problem is surgical delay of the muscle 
flap. Surgical delay provides better perfusion from the 
major vascular pedicle to the distal portion of the muscle 
and has been shown to improve latissimus dorsi muscle 
function for use in cardiomyoplasty. 5 This technique 
involves ligation of all the segmental vascular pedicles to 
the latissimus dorsi muscle except the most distal one, 
which is also ligated and cut while the flap is being ele- 
vated during a separate operation. 
However, need for a second surgical operation is a 
major concern. Also, thoracodorsal vessels are still the 
only vessels that are depended on for distal muscle 
perfusi0n. Risk of reduction in blood flow because of 
kinking of or pressure on the pedicle (which is passed 
from outside to the inside of the thorax), possible direct 
deleterious effects of the electrical current on the thora- 
codorsal vessels coursing between the two stimulation 
electrodes, possible damage to the vessels during elec- 
trode placement, and relative difficulty in handling of 
tissues during a second operation are the other issues that 
must be considered. 
I want to describe the use of an another technique to 
improve distal latissimus dorsi muscle perfusion in dy- 
namic cardiomyoplasty. This technique is called super- 
charging the flap and was developed to improve the 
pedicled transverse rectus abdominis flap perfusion in 
breast reconstruction. Application of this technique in 
cardiomyoplasty consists of anast0mosing an artery close 
to the new location of the muscle (e.g., internal thoracic 
artery) to one or two of the biggest distal perforating 
arteries of the latissimus dorsi muscle. This is done during 
the definitive operation. This procedure does not require 
a second surgical operation, provides perfusion of the 
distal muscle in a manner similar to its original form, and 
circumvents the other issues that I mentioned. 
Expanding the r search efforts in this direction will be 
helpfu ! in salvaging the future of this fascinating idea of 
skeletal muscle assistance to the failing heart. 
E. Tuncay (Tsti~ner, MD 
307-14 MDR Building 
Department of Surgery 
Division of Plastic and Reconstructive Surgery 
University of Louisville 
Louisville, KY 40292 
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